中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2013年
19期
5-6,9
,共3页
王元松%贾彩霞%迟秀娥%张忠勇%田凤胜%苏秀海
王元鬆%賈綵霞%遲秀娥%張忠勇%田鳳勝%囌秀海
왕원송%가채하%지수아%장충용%전봉성%소수해
糖尿病肾病%贝那普利%三黄益肾胶囊
糖尿病腎病%貝那普利%三黃益腎膠囊
당뇨병신병%패나보리%삼황익신효낭
Diabetic nephropathy%Benazrepril%Sanhuang Yishen capsule
目的:观察三黄益肾胶囊联合贝那普利治疗早期糖尿病肾病的疗效。方法:选取糖尿病肾病患者86例,随机分为对照组和治疗组,对照组在常规饮食和降糖药物治疗的基础上加用贝那普利(10mg,1次/d),治疗组在对照组基础上加用三黄益肾胶囊(5粒,3次/d),疗程1年。观察治疗前后患者中医症候积分、血脂、血糖、HbA1c、24h尿微量白蛋白排泄量、BUN、Cr的变化。结果:两组治疗后血糖、血脂、24h尿微量白蛋白排泄量较治疗前显著下降,差异有统计学意义(P<0.05,P<0.01);治疗组治疗后中医症候积分较治疗前及对照组治疗后明显下降,差异有统计学意义(P<0.05,P<0.01)。治疗组与对照组治疗后比较,24h尿微量白蛋白排泄量下降显著(P<0.05,P<0.01)。结论:三黄益肾胶囊联合贝那普利治疗糖尿病肾病能有效改善中医证候,降低尿白蛋白排泄量。
目的:觀察三黃益腎膠囊聯閤貝那普利治療早期糖尿病腎病的療效。方法:選取糖尿病腎病患者86例,隨機分為對照組和治療組,對照組在常規飲食和降糖藥物治療的基礎上加用貝那普利(10mg,1次/d),治療組在對照組基礎上加用三黃益腎膠囊(5粒,3次/d),療程1年。觀察治療前後患者中醫癥候積分、血脂、血糖、HbA1c、24h尿微量白蛋白排洩量、BUN、Cr的變化。結果:兩組治療後血糖、血脂、24h尿微量白蛋白排洩量較治療前顯著下降,差異有統計學意義(P<0.05,P<0.01);治療組治療後中醫癥候積分較治療前及對照組治療後明顯下降,差異有統計學意義(P<0.05,P<0.01)。治療組與對照組治療後比較,24h尿微量白蛋白排洩量下降顯著(P<0.05,P<0.01)。結論:三黃益腎膠囊聯閤貝那普利治療糖尿病腎病能有效改善中醫證候,降低尿白蛋白排洩量。
목적:관찰삼황익신효낭연합패나보리치료조기당뇨병신병적료효。방법:선취당뇨병신병환자86례,수궤분위대조조화치료조,대조조재상규음식화강당약물치료적기출상가용패나보리(10mg,1차/d),치료조재대조조기출상가용삼황익신효낭(5립,3차/d),료정1년。관찰치료전후환자중의증후적분、혈지、혈당、HbA1c、24h뇨미량백단백배설량、BUN、Cr적변화。결과:량조치료후혈당、혈지、24h뇨미량백단백배설량교치료전현저하강,차이유통계학의의(P<0.05,P<0.01);치료조치료후중의증후적분교치료전급대조조치료후명현하강,차이유통계학의의(P<0.05,P<0.01)。치료조여대조조치료후비교,24h뇨미량백단백배설량하강현저(P<0.05,P<0.01)。결론:삼황익신효낭연합패나보리치료당뇨병신병능유효개선중의증후,강저뇨백단백배설량。
Objective: To observe the effect of Sanhuang Yishen capsule combined with benazrepril treatment on early diabetic nephropathy (DN). Methods:86 patients were randomly assigned to the control group and the treated group.The control group on the basis of the conventional hypoglycemic treatment plused benazepril (10mg 1time/d) treat. Treated group was treated by Sanhuang Yishen capsule on the basis of control group, with a treatment course of one year for both group. We obserbved the changes of Chinese medicine syndrome scores, blood lipids, blood glucose, HbA1c, quantitor of 24 hours urine macroalbrum excretion, blood urine nitrogen (BUN) serum creatinine (Scr). Results: After treatment in the two groups, blood lipids, blood glucose and quantitor of 24 hours urine macroalbrum excretion were significantly lower than before treatment, and the difference was statistically significant (P<0.05, P<0.01). After treatment in the treated group, the Chinese medicine syndrome scores and quantitor of 24 hours urine macroalbrum excretion significantly reduced than in the control group and before treatment. The difference was statically significant (P<0.05, P<0.01). Conclusion:Sanhuang Yishen capsule combined with benazrepril treatment can effectively improve Chinese sydrome and reduce quantitor of urine macroalbrum excretion.